Paul Graham Fisher
Clinical Trials
- Not Recruiting XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
- Not Recruiting An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies
- Recruiting Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
- Recruiting Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
- Recruiting Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
- Recruiting Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
- Not Recruiting Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
- Not Recruiting Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
- Not Recruiting Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
- Not Recruiting Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy
- Not Recruiting Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment
- Not Recruiting Intrathecal and Systemic Chemotherapy Combined With Radiation Therapy in Treating Young Patients With Newly Diagnosed Central Nervous System Atypical Teratoid/Rhabdoid Tumors
- Not Recruiting Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas
- Not Recruiting XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
- Not Recruiting Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma
Help